Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation.
Advanced glycation end products (AGEs) accumulate in diabetic wounds as a result of the glycosylation of various proteins. Interaction of AGEs with the receptor for AGEs (RAGE) results in an exaggerated inflammatory response and compromised collagen production. These changes lead to impaired wound healing. A soluble form of RAGE (sRAGE) has been shown to bind AGEs and thereby blunt their pathogenetic effects. Using genetically diabetic C57BLks-db/db mice, the authors applied sRAGE topically to standardized full-thickness wounds to improve diabetic wound healing. They measured various parameters of wound healing such as neovascularization, reepithelialization, collagen formation, and granulation tissue area. Their results showed a statistically significant increase in granulation tissue area and microvascular density in the sRAGE group compared with untreated wounds. There was a trend toward a smaller epithelial gap in the sRAGE-treated group that did not reach statistical significance. The authors conclude that sRAGE may be a powerful treatment of accelerating diabetic wound healing.
Wear-Maggitti
Kelley
K
Columbia University College of Physicians and Surgeons, Division of Plastic and Reconstructive Surgery, New York, NY, USA.
Lee
James
J
Conejero
Alejandro
A
Schmidt
Anne Marie
AM
Grant
Robert
R
Breitbart
Arnold
A
D000287:Administration, Topical; D000818:Animals; D048909:Diabetes Complications; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006097:Granulation Tissue / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000008:administration & dosage*; D012867:Skin / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy / Q000209:etiology
D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic